This is a randomized, double-blind, 5-week intervention clinical study that aims to investigate the dose-dependent effects of Virtiva® Plus on stress, and cognitive performance in participants experiencing heightened stress. The occurrence of adverse events in response to daily supplementation of Virtiva® Plus will also be measured. The desired sample size for this study is 24 subjects. To account for potential dropouts, we aim to enroll up to 20% over the desired sample size. Therefore, this study will enroll up to 29 subjects. Subjects will be randomly divided into two study groups: low dose (240 mg/day) or high dose (480 mg/day) of Virtiva® Plus. For both groups, the dose will be divided into two equal servings. Blocked randomization will be deployed in which subjects are divided into blocks of 2 subjects and each subject within a block is randomly assigned to one of the two study groups. Participants will be asked to stop taking alternative supplements used for cognitive enhancement 7 days prior to study related cognitive testing assessments.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Generalized Anxiety Disorder-7 (GAD7)
Timeframe: Pre-Event, 5 weeks Post Event
Perceived Stress Scale - 10 (PSS-10)
Timeframe: Pre-Event, 5 weeks Post Event
Short Form 36 (SF-36)
Timeframe: Pre-Event, 5 weeks Post Event
Satisfaction with Life Scale (SWLS)
Timeframe: Pre-Event, 5 weeks Post Event
Positive emotion, Negative Emotion, Engagement, Relationships, Meaning, and Accomplishment (PERMA Profiler)
Timeframe: Pre-Event, 5 weeks Post Event
Dysfunctional Attitudes Scale-17 (DAS-17)
Timeframe: Pre-Event, 5 weeks Post Event
Everyday Cognition 12 Scale (ECog-12)
Timeframe: Pre-Event, 5 weeks Post Event
Abbreviated Profile of Mood States (POMS)
Timeframe: Pre-Event, 5 weeks Post Event